Clinically, it may be advisable to prioritize the use of NKCC1 inhibitors such as Bumetanide and Torasemide in high-risk KOA patients with hypertension or in those already diagnosed with KOA, and to conduct relevant clinical trials for validation. This evidence concerns the gene SLC12A2 and Hypertension.